San Diego’s Autobahn Therapeutics raises $32.7 million to pursue depression treatment

Startup plans to launch early level dosing trial for its mental fitness therapy later this year.

The organization, which changed into based on studies from Dr. Tom Scanlan of Oregon Health & Science University

 is growing a mind chemistry platform for vital anxious machine problems. 

Its drug candidate for depression makes a speciality of the position that thyroid hormone performs within the disorder.

Autobahn plans to start an early degree dosing trial for the drug later this yr.

2020, Autobahn raised $76 million in an preliminary round of funding to launch its operations.

 the company is subsidized by Cowen Healthcare Investments, BVF Partners, Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital, Alexandria Venture Investments and GT Healthcare.